Taken together with experimental studies of ACE2 null mice [37, 47–49] and studies of recombinant ACE2 treatment [50–52], these findings suggest that low ACE2 expression may contribute to the progression of CKD, by enhancing early inflammation and contributing to long-term fibrosis. Here, ACE2 is linked to chronic kidney disease.